CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published ahead of print on April 26, 2006
Clin J Am Soc Nephrol 1: 844-852, 2006
© 2006 American Society of Nephrology
doi: 10.2215/CJN.01701105
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
CJN.01701105v1
1/4/844    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vo, A. A.
Right arrow Articles by Jordan, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vo, A. A.
Right arrow Articles by Jordan, S. C.

Renal Transplantation

Safety and Adverse Events Profiles of Intravenous Gammaglobulin Products Used for Immunomodulation: A Single-Center Experience

Ashley A. Vo*, Vinh Cam*, Mieko Toyoda{dagger}, Dechu P. Puliyanda*, Marina Lukovsky*, Suphamai Bunnapradist*, Alice Peng*, Kai Yang{ddagger}, and Stanley C. Jordan*,{dagger}

* Comprehensive Transplant Center, {dagger} Transplant Immunology Laboratory, and {ddagger} Department of Medical Genetics, Cedars-Sinai Medical Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California

Address correspondence to: Dr. Ashley A. Vo, Center for Kidney Diseases & Transplantation, Cedars-Sinai Medical Center, 8635 W. 3rd Street, Suite 590W, Los Angeles, CA 90048. Phone: 310-423-2967; Fax: 310-423-6369; E-mail: ashley.vo{at}cshs.org

Intravenous Ig (IVIg) products are used in various medical conditions. Differences in excipients account for most adverse events (AE). Reports of complications including acute myocardial infarction (AMI) and acute renal failure (ARF) have emerged. Herein is described one institution’s experience with IVIg-related complications. This study is a retrospective analysis of infusion-related AE that are associated with various IVIg products. Infusion-related AE were monitored during and after the administration of three IVIg products: Gamimune-N 10% (n = 76), Polygam (n = 105), and Carimune (n = 98). AE segregated to specific IVIg products. No patients who received Gamimune-N experienced AMI or ARF. Five (4.7%) patients (P < 0.01) in the Polygam group experienced AMI. Eight (8.2%) patients (P < 0.0001) in the Carimune group developed ARF. IVIg was safe to give on hemodialysis. IVIg products differ in osmolality, pH, and sugar and sodium content; this results in specific AE. Polygam resulted in no ARF but an increase in AMI. Carimune products at 9% concentration resulted in an increase in ARF. Gamimune-N 10% and other IVIg products were frequently associated with headaches. Administration of IVIg to patients who are on hemodialysis seems to be safe and effective.




This article has been cited by other articles:


Home page
 NEJMHome page
C. Fourtounas, A. Mouzaki, J. G. Vlachojannis, S. C. Jordan, A. A. Vo, and N. L. Reinsmoen
Desensitization during Renal Transplantation
N. Engl. J. Med., October 16, 2008; 359(16): 1731 - 1732.
[Full Text] [PDF]

Home page
 CJASNHome page
G. Bollee, D. Anglicheau, A. Loupy, J. Zuber, N. Patey, D. M. Gregor, F. Martinez, M.-F. Mamzer-Bruneel, R. Snanoudj, E. Thervet, et al.
High-Dosage Intravenous Immunoglobulin-Associated Macrovacuoles Are Associated with Chronic Tubulointerstitial Lesion Worsening in Renal Transplant Recipients
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1461 - 1468.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society of Nephrology.